-
公开(公告)号：US20240350667A1
公开(公告)日：2024-10-24
申请号：US18685681
申请日：2022-07-22
Applicant: Spark Therapeutics, Inc.
Inventor： Xavier Anguel , Pedro Cejas , Ali Nahvi , Mustafa Yazicioglu, III , Rui Zhang
IPC: A61K48/00 , A61K9/127 , A61K9/51 , A61K31/404 , A61K31/437 , A61K45/06 , C12N15/88
CPC classification number: A61K48/005 , A61K9/127 , A61K9/5123 , A61K31/404 , A61K31/437 , A61K45/06 , A61K48/0083 , C12N15/88
Abstract: The present invention features method and composition that can be used to facilitate intracellular delivery of DNA to a subject. The provided methods and compositions employ a nanoparticle for intracellular DNA delivery and a cytosolic DNA-sensing inhibitor. The cytosolic DNA-sensing inhibitor is provided to decrease the subject's immune response that can be stimulated by the DNA.
-
公开(公告)号：US20240350462A1
公开(公告)日：2024-10-24
申请号：US18527060
申请日：2023-12-01
Applicant: Selecta Biosciences, Inc.
Inventor： Takashi Kei Kishimoto
IPC: A61K31/436 , A61K9/00 , A61K9/127 , A61K9/51 , A61K31/192 , A61K38/19 , A61K38/21 , A61K38/37 , A61K38/43 , A61K38/47 , A61K39/00 , A61K39/395 , A61K45/06 , A61K47/69 , C07K16/18 , C07K16/24 , C07K16/40
CPC classification number: A61K31/436 , A61K9/0019 , A61K9/127 , A61K9/5115 , A61K9/5153 , A61K9/5192 , A61K31/192 , A61K38/19 , A61K38/21 , A61K38/37 , A61K38/43 , A61K38/47 , A61K39/39533 , A61K39/3955 , A61K45/06 , A61K47/6923 , A61K47/6929 , A61K47/6935 , A61K47/6937 , C07K16/18 , C07K16/241 , C07K16/40 , A61K2039/505 , C12Y305/01001
Abstract: This invention relates to methods that provide immunosuppressants and therapeutic macromolecules that are administered within a pharmacodynamically effective window of the immunosuppressants to induce immune tolerance to the therapeutic macromolecules. The methods allow shifting the immune response in favor of tolerogenic immune response development specific to the therapeutic macromolecule.
-
公开(公告)号：US20240335380A1
公开(公告)日：2024-10-10
申请号：US18533497
申请日：2023-12-08
Applicant: Biofrontera Bioscience GmbH
Inventor： Montserrat FOGUET , Lars MÖLLMANN
IPC: A61K9/107 , A61K9/127 , A61K41/00 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/24 , A61K47/26 , A61K47/36
CPC classification number: A61K9/1075 , A61K9/127 , A61K41/0061 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/24 , A61K47/26 , A61K47/36
Abstract: The present invention relates to oil in water nanoemulsions which are essentially free of propylene glycol. The nanovesicle formulations are particularly stable in regard to shelf life at different storage temperatures.
-
公开(公告)号：US20240309077A1
公开(公告)日：2024-09-19
申请号：US18436678
申请日：2024-02-08
Applicant: Washington University
Inventor： David Holtzman , Hong Jiang , Thu Nga Bien-Ly , Mark S. Dennis , Jing Guo , Adam P. Silverman , Ryan J. Watts , Yin Zhang
CPC classification number: C07K16/18 , A61K9/0019 , A61K9/0085 , A61K9/127 , A61K31/192 , A61P25/28 , A61K2039/505 , C07K2317/33 , C07K2317/90 , C07K2317/92
Abstract: The present disclosure encompasses compositions and methods for effectively treating at least one symptom or sign of Aβ plaque or cerebral amyloid angiopathy (CAA) associated symptoms, or for decreasing amyloid plaque load or CAA load. The method comprises administering an effective amount of an anti-ApoE antibody to a mammalian subject, such as to a human.
-
公开(公告)号：US20240307307A1
公开(公告)日：2024-09-19
申请号：US18468102
申请日：2023-09-15
Applicant: KABUSHIKI KAISHA TOSHIBA
Inventor： Emi NOZAKI , Eiichi AKAHOSHI , Mitsuko ISHIHARA
Abstract: According to one embodiment, a lipid composition is for delivering an objective substance to a target cell. The composition is contacted with the target cell under an environment of 37° C. or higher. The composition includes a substance delivery carrier having lipid particle and an objective substance encapsulated in the lipid particle. The lipid particle constitutes a liposome and includes FFT-10 and/or FFT-20 as constituents thereof.
-
Patent Agency Ranking
公开(公告)号：US20240307306A1
公开(公告)日：2024-09-19
申请号：US18612639
申请日：2024-03-21
Applicant: Waterford Institute of Technology
Inventor： Gautam BEHL , Sangeeta KUMARI , Niall O'REILLY , Orla O'DONOVAN , Peter MCLOUGHLIN , David KENT , Laurence FITZHENRY
CPC classification number: A61K9/1075 , A61K9/127 , A61K9/51 , B82Y5/00 , B82Y40/00
Abstract: This invention relates to a composition for ophthalmic delivery of a therapeutic agent, the composition comprising an oil-in-water (o/w) microemulsion comprising a fatty acid, or fatty acid ester, as the oil phase; an aqueous phase; a surfactant; and a co-surfactant, and wherein the composition further comprise a suspension of therapeutic agent-loaded nanoparticles. Use of the composition for the treatment or prevention of an eye disorder, a method of treatment or prevention of an eye disorder and an eye drop dispenser are also provided.
-
公开(公告)号：US20240299553A1
公开(公告)日：2024-09-12
申请号：US18572447
申请日：2022-06-21
Inventor： Dmitri Simberg , Hanmant Gaikwad , Irina Balyasnikova
CPC classification number: A61K47/543 , A61K9/127 , A61K9/5123 , A61K47/6911 , A61K47/6929
Abstract: The present disclosure relates in one aspect to constructs comprising a lipophilic membrane dye covalently linked through a linker to a cargo. In another aspect, the present disclosure relates to a method of delivering a cargo to a tumor in a subject in need thereof, the method comprising administering a construct of the disclosure to the subject. In certain embodiments, the tumor is a brain tumor.
-
公开(公告)号：US20240299489A9
公开(公告)日：2024-09-12
申请号：US17449679
申请日：2021-10-01
Applicant: Translate Bio, Inc.
Inventor： Michael Heartlein , Frank DeRosa , Alan Kimura , Jonathan Abysalh , Anusha Dias , Shrirang Karve , Zarna Patel
CPC classification number: A61K38/1709 , A61K9/0078 , A61K9/127 , A61K48/0075 , A61P11/12 , C12N15/88
Abstract: The present invention provides, among other things, methods of treating cystic fibrosis, comprising a step of administering to a subject in need of treatment a composition comprising an mRNA encoding a Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, wherein the mRNA encoding the CFTR protein comprises a polynucleotide sequence at least 80% identical to SEQ ID NO: 1, wherein the mRNA is at a concentration of at least 0.4 mg/mL, and wherein the step of administering comprises inhalation.
-
公开(公告)号：US12083218B2
公开(公告)日：2024-09-10
申请号：US17447453
申请日：2021-09-13
Applicant: Johnson & Johnson Consumer Inc.
Inventor： Gregory E. Koll , Gerard P. McNally , Vipul Dave
CPC classification number: A61K9/0056 , A23L27/33 , A23L27/84 , A23L33/10 , A61K9/127 , A61K31/426
Abstract: The invention relates to a soft chewable dosage form comprising a first active pharmaceutical ingredient encapsulated in a lipid material that is embedded in the soft chewable dosage form and wherein the soft chewable dosage form comprises at least a second active pharmaceutical ingredient as well as a method of treating a subject suffering from a disease or disorder in the gastro intestinal tract using the soft chewable dosage form.
-
公开(公告)号：US12076438B2
公开(公告)日：2024-09-03
申请号：US17066919
申请日：2020-10-09
Applicant: Translate Bio, Inc.
Inventor： Christian Cobaugh , Richard Wooster , Frank DeRosa , Anusha Dias , Shrirang Karve
CPC classification number: A61K9/127 , A61K9/0019 , A61K9/007 , A61K9/0078 , A61K38/1709 , A61K38/19 , A61K38/193 , A61K38/208 , A61K45/06 , A61P35/00
Abstract: The present invention provides, among other things, methods and compositions for cancer treatment. The methods and compositions disclosed herein are particularly effective in reducing the size/volume of a tumor and inhibiting tumor growth.
-
-
-
-
-
-
-
-
-
Search Results
5322
records
(took 0.03 seconds)
